Astrocytoma

Last updated
Astrocytoma
Astrocytoma.jpg
Two PET images—the upper of which shows a normal brain and the lower shows astrocytoma
Specialty Neuro-oncology, neurosurgery

Astrocytoma is a type of brain tumor. Astrocytomas (also astrocytomata) originate from a specific kind of star-shaped glial cell in the cerebrum called an astrocyte. This type of tumor does not usually spread outside the brain and spinal cord and it does not usually affect other organs. After glioblastomas, astrocytomas are the second most common glioma and can occur in most parts of the brain and occasionally in the spinal cord. [1]

Contents

Within the astrocytomas, two broad classes are recognized in literature, those with:

People can develop astrocytomas at any age. The low-grade type is more often found in children or young adults, while the high-grade type is more prevalent in adults. Astrocytomas in the base of the brain are more common in young people and account for roughly 75% of neuroepithelial tumors. [3]

Pathophysiology

Astrocytoma causes regional effects by compression, invasion, and destruction of brain parenchyma, arterial and venous hypoxia, competition for nutrients, release of metabolic end products (e.g., free radicals, altered electrolytes, neurotransmitters), and release and recruitment of cellular mediators (e.g., cytokines) that disrupt normal parenchymal function. [2] Secondary clinical sequelae may be caused by elevated intracranial pressure attributable to direct mass effect, increased blood volume, or increased cerebrospinal fluid volume. [2]

Genetic and Molecular alterations

Homozygous deletion of CDKN2A/B is the main feature of high grade astrocytoma. In addition, a genome-wide pattern of DNA copy-number alterations (CNAs) has been uncovered, which is correlated with a patient's survival and response to treatment. This pattern identifies among lower-grade astrocytoma patients a subtype, where the CNA genotype is correlated with an approximately one-year survival phenotype. [4] [5]

Diagnosis

An X-ray computed tomography (CT) or magnetic resonance imaging (MRI) scan is necessary to characterize the extent of these tumors (size, location, consistency). CT will usually show distortion of third and lateral ventricles with displacement of anterior and middle cerebral arteries. Histologic analysis is necessary for grading diagnosis.[ citation needed ]

In the first stage of diagnosis the doctor will take a history of symptoms and perform a basic neurological exam, including an eye exam and tests of vision, balance, coordination, and mental status. The doctor will then require a CT scan and MRI of the patient's brain. During a CT scan, X-rays of the patient's brain are taken from many different directions. These are then combined by a computer, producing a cross-sectional image of the brain. For an MRI, the patient relaxes in a tunnel-like instrument while the brain is subjected to changes of magnetic field. An image is produced based on the behavior of the brain's water molecules in response to the magnetic fields. A special dye may be injected into a vein before these scans to provide contrast and make tumors easier to identify.[ citation needed ]

If a tumor is found, a neurosurgeon must perform a biopsy on it. This simply involves the removal of a small amount of tumor tissue, which is then sent to a neuropathologist for examination and grading. The biopsy may take place before surgical removal of the tumor or the sample may be taken during surgery. Grading of the tumor sample is a method of classification that helps the doctor to determine the severity of the astrocytoma and to decide on the best treatment options. The neuropathologist grades the tumor by looking for atypical cells, the growth of new blood vessels, and for indicators of cell division called mitotic figures.[ citation needed ]

Grading

Of numerous grading systems in use for the classification of tumor of the central nervous system, the World Health Organization (WHO) grading system is commonly used for astrocytoma. Established in 1993 in an effort to eliminate confusion regarding diagnoses, the WHO system established a four-tiered histologic grading guideline for astrocytomas that assigns a grade from 1 to 4, with 1 being the least aggressive and 4 being the most aggressive.[ citation needed ]

The WHO grading scheme is based on the appearance of certain characteristics: atypia, mitosis, endothelial proliferation, and necrosis. These features reflect the malignant potential of the tumor in terms of invasion and growth rate. Various types of astrocytomas are given these WHO grades:

WHO gradeAstrocytomasDescription
IConsist of slow-growing astrocytomas, benign, and associated with long-term survival. Individuals with very slow-growing tumors where complete surgical removal by stereotactic surgery is possible may experience total remission. [6] Even if the surgeon is not able to remove the entire tumor, it may remain inactive or be successfully treated with radiation.
IIConsist of relatively slow-growing astrocytomas, usually considered benign that sometimes evolve into more malignant or as higher grade tumors. They are prevalent in younger people who often present with seizures. Median survival varies with the cell type of the tumor. Grade 2 astrocytomas are defined as being invasive gliomas, meaning that the tumor cells penetrate into the surrounding normal brain, making a surgical cure more difficult. People with oligodendrogliomas (which might share common cells of origin [7] ) have better prognoses than those with mixed oligoastrocytomas, who in turn have better prognoses than patients with (pure) low-grade astrocytomas. Other factors which influence survival include age (younger the better) and performance status (ability to perform tasks of daily living). Due to the infiltrative nature of these tumors, recurrences are relatively common. Depending on the patient, radiation or chemotherapy after surgery is an option. Individuals with grade 2 astrocytoma have a 5-year survival rate of about 34% without treatment and about 70% with radiation therapy. [6] The median survival time is 4 years. [6]
IIIConsist of anaplastic astrocytomas. It is often related to seizures, neurologic deficits, headaches, or changes in mental status. The standard initial treatment is to remove as much of the tumor as possible without worsening neurologic deficits. Radiation therapy has been shown to prolong survival and is a standard component of treatment. Individuals with grade 3 astrocytoma have a median survival time of 18 months without treatment (radiation and chemotherapy). [6] There is no proven benefit to adjuvant chemotherapy or supplementing other treatments for this kind of tumor. Although temozolomide is effective for treating recurrent anaplastic astrocytoma, its role as an adjuvant to radiation therapy has not been fully tested.
IV
  • Grade 4 Astrocytoma
Consists of grade 4 astrocytoma (as of WHO 2021) that form following high-grade transformation of low-grade astrocytoma. These are more common in younger patients (mean age 45 versus 62 years). [7] Surgical removal remains the mainstay of treatment, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible. Although radiotherapy rarely cures glioblastoma, studies show that it doubles the median survival of patients, compared to supportive care alone. [8] The prognosis is worst for these grade 4 gliomas. Few patients survive beyond 3 years. Individuals with grade 4 astrocytoma have a median survival time of 17 [6] weeks without treatment, 30 [6] weeks with radiation, and 37 [6] weeks with surgical removal of most of the tumor followed by radiation therapy. Long-term survival (at least five years) falls well under 3%. [9] [10]
Diagnosis of diffuse glioma, with astrocytomas mainly being diagnosed under IDH mutant and nuclear ATRX lost. Diagnosis of diffuse glioma.png
Diagnosis of diffuse glioma, with astrocytomas mainly being diagnosed under IDH mutant and nuclear ATRX lost.

According to the WHO data, the lowest grade astrocytomas (grade I) make up only 2% of recorded astrocytomas, grade II 8%, and the higher grade anaplastic astrocytomas (grade III) 20%. The highest graded astrocytoma (grade IV GBM) is the most common primary nervous system cancer and second most frequent brain tumor after brain metastasis. Despite the low incidence of astrocytomas compared to other human cancers, mortality is significant, as the higher grades (III & IV) present high mortality rates (mainly due to late detection of the neoplasm).[ citation needed ]

Prevention

There are no precise guidelines because the exact cause of astrocytoma is not known.[ citation needed ]

Treatment

Management of IDH-mutant gliomas, with astrocytomas at center and right. Management of IDH-mutant glioma.png
Management of IDH-mutant gliomas, with astrocytomas at center and right.

For low-grade astrocytomas, removal of the tumor generally allows functional survival for many years. In some reports, the 5-year survival has been over 90% with well-resected tumors. Indeed, broad intervention of low-grade conditions is a contested matter. In particular, pilocytic astrocytomas are commonly indolent bodies that may permit normal neurologic function. However, left unattended, these tumors may eventually undergo neoplastic transformation. To date, complete resection of high-grade astrocytomas is impossible because of the diffuse infiltration of tumor cells into normal parenchyma. Thus, high-grade astrocytomas inevitably recur after initial surgery or therapy and are usually treated similarly to the initial tumor. Despite decades of therapeutic research, curative intervention is still nonexistent for high-grade astrocytomas; patient care ultimately focuses on palliative management. [3]

Society and culture

Notable cases

In March 1990, United States Republican Party political strategist Lee Atwater was diagnosed with astrocytoma after a tumor was found in his right parietal lobe. After undergoing radiation therapy (including the then-new implant radiation treatment), Atwater died the following year at the age of 40. [12]

Long-time U.S. Senator Ted Kennedy (D-MA) died of malignant glioma. [13]

University of Texas sniper Charles Whitman, who killed multiple people during a mass murder event in 1966, was diagnosed with astrocytoma post-mortem. The Connally Commission investigating the shooting concluded the tumor "conceivably could have contributed to his inability to control his emotions and actions". [14]

Major League pitcher Dan Quisenberry was diagnosed with grade IV astrocytoma in January 1998. He died age 45 in 1998 in Leawood, Kansas. [15]

Richard Burns, winner of the 2001 World Rally Championship, was diagnosed with astrocytoma in 2003. Four years to the day after winning the World Rally Championship, on 25 November 2005, Burns died in Westminster, London, [16] aged 34, after having been in a coma for some days as a result of his brain tumour. [17]

Professional wrestler Matt Cappotelli was diagnosed with a grade 2/3 astrocytoma in December 2005, scuttling plans to promote Cappottelli to the main WWE roster. Cappotelli, who won a contract with WWE through the third season of their reality program Tough Enough, was the Ohio Valley Wrestling Heavyweight Champion at the time of his diagnosis and vacated the title in February 2006 [18] after confirming the tumor was cancerous. Cappotelli underwent successful surgery and chemotherapy, [19] [20] [21] but was unable to return to active wrestling work. He did return to OVW as a trainer in 2013. [22] [23] He died on June 29, 2018. [24]

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Glioma</span> Tumour of the glial cells of the brain or spine

A glioma is a type of primary tumor that starts in the glial cells of the brain or spinal cord. They are cancerous but some are extremely slow to develop. Gliomas comprise about 30 percent of all brain tumors and central nervous system tumours, and 80 percent of all malignant brain tumours.

<span class="mw-page-title-main">Matt Cappotelli</span> American professional wrestler

Matthew Lee Cappotelli was an American professional wrestler. After co-winning Tough Enough III with John Hennigan, he worked in Ohio Valley Wrestling (OVW), the primary developmental territory for WWE. He ended his career due to a malignant brain tumor.

<span class="mw-page-title-main">Oligodendroglioma</span> Medical condition

Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. They occur primarily in adults but are also found in children.

<span class="mw-page-title-main">Glioblastoma</span> Aggressive type of brain cancer

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

<span class="mw-page-title-main">Oligoastrocytoma</span> Medical condition

Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell origin, astrocytoma and oligodendroglioma. However, the term "Oligoastrocytoma" is now considered obsolete by the National Comprehensive Cancer Network stating "the term should no longer be used as such morphologically ambiguous tumors can be reliably resolved into astrocytomas and oligodendrogliomas with molecular testing."

<span class="mw-page-title-main">Pilocytic astrocytoma</span> Benign brain tumor originating in astrocyte cells

Pilocytic astrocytoma is a brain tumor that occurs most commonly in children and young adults. They usually arise in the cerebellum, near the brainstem, in the hypothalamic region, or the optic chiasm, but they may occur in any area where astrocytes are present, including the cerebral hemispheres and the spinal cord. These tumors are usually slow growing and benign, corresponding to WHO malignancy grade 1.

<span class="mw-page-title-main">Brain biopsy</span> Diagnostic procedure of brain tissue sample

Brain biopsy is the removal of a small piece of brain tissue for the diagnosis of abnormalities of the brain. It is used to diagnose tumors, infection, inflammation, and other brain disorders. By examining the tissue sample under a microscope, the biopsy sample provides information about the appropriate diagnosis and treatment.

<span class="mw-page-title-main">Atypical teratoid rhabdoid tumor</span> Medical condition

An atypical teratoid rhabdoid tumor (AT/RT) is a rare tumor usually diagnosed in childhood. Although usually a brain tumor, AT/RT can occur anywhere in the central nervous system (CNS), including the spinal cord. About 60% will be in the posterior cranial fossa. One review estimated 52% in the posterior fossa, 39% are supratentorial primitive neuroectodermal tumors (sPNET), 5% are in the pineal, 2% are spinal, and 2% are multifocal.

<span class="mw-page-title-main">Pineoblastoma</span> Cancerous tumor of the pineal gland

Pineoblastoma is a malignant tumor of the pineal gland. A pineoblastoma is a supratentorial midline primitive neuroectodermal tumor. Pineoblastoma can present at any age, but is most common in young children. They account for 0.001% of all primary CNS neoplasms.

<span class="mw-page-title-main">Giant-cell glioblastoma</span> Tumor of the central nervous system

The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of bizarre, multinucleated giant cells.

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening. Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade astrocytoma/oligodendroglioma are among the worst. In these cases, untreated survival usually amounts to only a few months, and survival with current radiation and chemotherapy treatments may extend that time from around a year to a year and a half, possibly two or more, depending on the patient's condition, immune function, treatments used, and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant brain cancers tend to regenerate and emerge from remission easily, especially highly malignant cases. In such cases, the goal is to excise as much of the mass and as much of the tumor margin as possible without endangering vital functions or other important cognitive abilities. The Journal of Neuro-Oncology is the longest continuously published journal in the field and serves as a leading reference to those practicing in the area of neuro-oncology.

<span class="mw-page-title-main">Fibrillary astrocytoma</span> Type of brain tumor

Fibrillary astrocytomas are a group of primary slow-growing brain tumors that typically occur in adults between the ages of 20 and 50.

<span class="mw-page-title-main">Anaplastic astrocytoma</span> Medical condition

Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the brain. In the United States, the annual incidence rate for anaplastic astrocytoma is 0.44 per 100,000 people.

<span class="mw-page-title-main">Subependymal giant cell astrocytoma</span> Medical condition

Subependymal giant cell astrocytoma is a low-grade astrocytic brain tumor (astrocytoma) that arises within the ventricles of the brain. It is most commonly associated with tuberous sclerosis complex (TSC). Although it is a low-grade tumor, its location can potentially obstruct the ventricles and lead to hydrocephalus.

<span class="mw-page-title-main">Computed tomography of the head</span> Cross-sectional X-rays of the head

Computed tomography of the head uses a series of X-rays in a CT scan of the head taken from many different directions; the resulting data is transformed into a series of cross sections of the brain using a computer program. CT images of the head are used to investigate and diagnose brain injuries and other neurological conditions, as well as other conditions involving the skull or sinuses; it used to guide some brain surgery procedures as well. CT scans expose the person getting them to ionizing radiation which has a risk of eventually causing cancer; some people have allergic reactions to contrast agents that are used in some CT procedures.

<span class="mw-page-title-main">Diffuse midline glioma</span> Highly aggressive brain tumor, mostly found in children

Diffuse midline glioma, H3 K27-altered (DMG) is a fatal tumour that arises in midline structures of the brain, most commonly the brainstem, thalamus and spinal cord. When located in the pons it is also known as diffuse intrinsic pontine glioma (DIPG).

A central nervous system tumor is an abnormal growth of cells from the tissues of the brain or spinal cord. CNS tumor is a generic term encompassing over 120 distinct tumor types. Common symptoms of CNS tumors include vomiting, headache, changes in vision, nausea, and seizures. A CNS tumor can be detected and classified via neurological examination, medical imaging, such as x-ray imaging, magnetic resonance imaging (MRI) or computed tomography (CT), or after analysis of a biopsy.

<span class="mw-page-title-main">Anaplastic oligodendroglioma</span> Human brain tumor

Anaplastic oligodendroglioma is a neuroepithelial tumor which is believed to originate from oligodendrocytes, a cell type of the glia. In the World Health Organization (WHO) classification of brain tumors, anaplastic oligodendrogliomas are classified as grade III. In the course of the disease, it can degenerate into highly malignant oligodendroglioma, grade IV. The vast majority of oligodendrogliomas occur sporadically, without a confirmed cause and without inheritance within a family.

<span class="mw-page-title-main">Angiocentric glioma</span>

Angiocentric glioma (AG) refers to a rare neuroepithelial tumor when the superficial brain malignant cells enclose the brain vessels, commonly found in children and young adults. Initially identified in 2005 by Wang and his team from the University of Texas, AG was classified as Grade I by 2007 WHO Classification of Tumors of the Central Nervous System due to its benign clinical behavior, low proliferation index, and curative properties. AG primarily affects children and young adults at an average initial diagnosis age of 16 years old. Over 85% AG patients experience intractable seizures since childhood, especially partial epilepsy.

References

  1. ↑ "What Is Astrocytoma?". WebMD. Retrieved 1 July 2021.
  2. 1 2 3 Astrocytoma at eMedicine
  3. 1 2 "Astrocytoma". The Lecturio Medical Concept Library. Retrieved 1 July 2021.
  4. ↑ C. H. Lee*; B. O. Alpert*; P. Sankaranarayanan; O. Alter (January 2012). "GSVD Comparison of Patient-Matched Normal and Tumor aCGH Profiles Reveals Global Copy-Number Alterations Predicting Glioblastoma Multiforme Survival". PLOS ONE. 7 (1): e30098. Bibcode:2012PLoSO...730098L. doi: 10.1371/journal.pone.0030098 . PMC   3264559 . PMID   22291905. Highlight.
  5. ↑ S. P. Ponnapalli, et int.; O. Alter (May 2020). "Retrospective Clinical Trial Experimentally Validates Glioblastoma Genome-Wide Pattern of DNA Copy-Number Alterations Predictor of Survival". APL Bioengineering. 4 (2): 026106. doi: 10.1063/1.5142559 . PMC   7229984 . PMID   32478280. Press Release.
  6. 1 2 3 4 5 6 7 mdguidelines.com Astrocytoma Archived 2017-11-30 at the Wayback Machine Retrieved on Mars 26, 2010
  7. 1 2 Ohgaki, Hiroko; Kleihues, Paul (2009). "Genetic alterations and signaling pathways in the evolution of gliomas". Cancer Science. 100 (12): 2235–41. doi: 10.1111/j.1349-7006.2009.01308.x . PMC   11159448 . PMID   19737147. S2CID   16742915.
  8. ↑ "Glioma - Symptoms and causes". Mayo Clinic.
  9. ↑ Buckner, Jan C.; Brown, Paul D.; O'Neill, Brian P.; Meyer, Fredric B.; Wetmore, Cynthia J.; Uhm, Joon H. (2007). "Central Nervous System Tumors". Mayo Clinic Proceedings. 82 (10): 1271–86. doi:10.4065/82.10.1271. PMID   17908533.
  10. ↑ "CBTRUS - CBTRUS". CBTRUS.
  11. 1 2 Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G; et al. (2021). "EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood". Nat Rev Clin Oncol. 18 (3): 170–186. doi:10.1038/s41571-020-00447-z. PMC   7904519 . PMID   33293629.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    "This article is licensed under a Creative Commons Attribution 4.0 International License"
  12. ↑ Brady, John (December 1, 1996). "I'm Still Lee Atwater", The Washington Post , retrieved 2010-04-11.
  13. ↑ "Kennedy fought aggressive cancer". CNN. August 26, 2009. Retrieved 2010-02-27.
  14. ↑ Waring, Thomas R., ed. "Jury Blames Tumor For Killings: Doctor Says Whitman Unaffected"" The News and Courier [Charleston] 05 Aug. 1966: 9B. Print.
  15. ↑ Henderson, Heather (1999). "Dan Quisenberry - In His Own Words" The 1999 Big Bad Baseball Annual. Retrieved June 24, 2013.
  16. ↑ "Deaths England and Wales 1984–2006". Archived from the original on 2009-08-31. Retrieved 2015-11-25.
  17. ↑ "Former world champion Burns dies". bbc.co.uk. 26 November 2005. Retrieved 25 February 2008.
  18. ↑ Brady, Hicks. "2006: The year in wrestling". PWI Presents: 2007 Wrestling Almanac and book of facts. Kappa Publications. p. 17. 2007 Edition.
  19. ↑ Dee, Louie (2007-04-06). "Matt Cappotelli to undergo brain surgery". WWE.
  20. ↑ "Cappotelli undergoes surgery". World Wrestling Entertainment. 2007-05-01. Retrieved 2015-08-26.
  21. ↑ "Cappotelli recovering well". World Wrestling Entertainment. 2007-05-09.
  22. ↑ "Helping wrestlers get a grip". The Courier-Journal . Louisville, KY. 2013-11-12. Retrieved 2015-08-26.
  23. ↑ "Matt Cappotelli Beginner's Program". Ohio Valley Wrestling . Archived from the original on 2015-08-20. Retrieved 2015-08-26.
  24. ↑ Xu, Linda (June 29, 2018). "Matt Cappotelli, Former WWE Wrestler and 'Tough Enough' Winner, Dies at 38". TheWrap . Retrieved June 29, 2018.

Bibliography

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.